by Friedrich–Alexander University Erlangen–Nurnberg

Intranasal rIL-3 application during challenge induces Treg cells. (A) Experimental design for lung ILC2 skewing. (B) After 5 days of in vitro ILC2 differentiation, IL-10 release was measured in the supernatants of ILC2 skewed from the lung of wild-type (WT) asthmatic mice with and without additional rIL-3 treatment during sensitization or challenge phase (n = 6/7/7). (C) TGF-beta level in 24-h unstimulated lung cell culture, measured by ELISA (n = 6/7/4). (D) Flow cytometry analysis of Foxp3+CD25+CD4+ regulatory T cells in total lung cells. A representative dot plot is shown for each group (n = 6/7/7). (E) Summary of the immunoregulatory role of IL-3 in allergic asthma. Data are presented as means ± SEMs. One-way ANOVA or Kruskal–Wallis test was used to calculate statistical significance. ***p ≤ 0.001. Credit: Frontiers in Immunology (2022). DOI: 10.3389/fimmu.2022.821658

The messenger substance interleukin-3 produced by the body was previously considered to be pro-inflammatory in bronchial asthma. A research team from Universitätsklinikum Erlangen has now shown for the first time that the administration of interleukin-3, or IL-3 for short, can have a positive effect on chronic inflammatory respiratory disease.

Members of the research group led by Prof. Susetta Finotto, MD, and doctoral candidate and pharmacist Susanne Krammer from the Department of Molecular Pneumology investigated the production of the messenger substance in healthy preschool children and those affected by asthma who had participated in the European PreDicta pediatric asthma study. They found that children whose asthma was considered controlled by inhaled corticosteroid therapy had higher IL-3 production caused by blood cells known as activated peripheral blood lymphocytes. There was also a positive correlation between IL-3 in nasal fluid and the anti-inflammatory soluble form of the ST2 receptor. This suggests that IL-3 may contribute to alleviating asthma.

Using mice models induced with asthma, the researchers also investigated whether intranasal administration of IL-3 during asthma provocation could actually improve asthma symptoms. They discovered that IL-3 has a regulatory effect on the immune system and induces certain immune cells called regulatory T cells, which are believed to play a role in relieving bronchial asthma. Administration of IL-3 also decreased the number of pro-inflammatory eosinophil cells and reduced mucus production in the lungs of asthmatic mice.

IL-3 also resulted in decreased activation of inflammatory innate lymphoid type 2 cells. These immune cells secrete substances that can participate in the development of allergic diseases. They showed lower cell surface expression of the pro-inflammatory bound receptor ST2, which is important for activation of this cell type, when IL-3 was administered. The research group led by Prof. Finotto and Susanne Krammer have clearly shown that IL-3 also has immunoregulatory properties that can improve symptoms in bronchial asthma.

More information: Susanne Krammer et al, An Immunoregulatory Role of Interleukin-3 in Allergic Asthma, Frontiers in Immunology (2022). DOI: 10.3389/fimmu.2022.821658

Journal information: Frontiers in Immunology 

Provided by Friedrich–Alexander University Erlangen–Nurnberg